August 17, 2018
Memo to investors, what dramatically spikes up on low volume will more than probably go down
Pre-open indications: 3 trades, 1 BUY and 2 SELLs
Who do you call for “share side” assistance? It’s not AAA … try RMi to shed light on share pricing events and today’s session values.
While many talk about the shift in alternating sentiment, I monitor the pulse and focus of possible indications and outcomes!
U.S. stock index futures are slipping
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through!
Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates;
.... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
August 17, 2018
There are “signposts” that provide early warning of sector “oversights”; probabilities trigger momentum!
Pre-open indications: 4 HITs and 2 MISS
Out and about: If you had followed the recommendation of SELLING the three (3) of the gene “editors” – CRSP, EDIT and NTLA, you would have profited!
I won’t apologize for being a “Devil’s Advocate” challenging views or consensus by building a better or possible case for an alternative explanation.
Presenting alternative hypotheses clarifies material facts and evidence available to investors. “Devil’s Advocacy” also provides greater confidence that the current sector outlook will hold-up to close scrutiny!
Subscribe!
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through! Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates; .... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
August 16, 2018
Indication intelligence collects and analyzes sector information to sort-out weaknesses, vulnerabilities and strengths I know you have seen, read and appreciate RMi’s interpretation and sometimes clarification of news, perception and actionable intelligence including a pricing metric. I make a commitment to provide need-to-know “facts in evidence” with first, fast, and furious editions of what’s happening in the cell and gene therapy, immune-oncology and regenerative medicine sector even as or before news unfolds! Now I’m asking you to commit: http://www.regmedinvestors.com/create-account
August 15, 2018
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies Thirty-five (35) LPS, four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies; The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
August 17, 2018
RegMed Investors’ (RMi) closing bell: examine the knowns, unknowns and some probable actions
August 17, 2018
Gene editing stocks, time to harvest some upside?
August 17, 2018
RegMed Investors’ (RMi) pre-open: the sector is what it is, until it isn’t and even then it doesn’t seem to be…
August 16, 2018
RegMed Investors’ (RMi) closing bell: the sector had the wind at its back
August 16, 2018
RegMed Investors’ (RMi): call me crazy if I had all the answers but, I have more than most …
August 16, 2018
RegMed Investors’ (RMi) pre-open: hoping and praying for a rebound of the oversold
August 15, 2018
RegMed Investors’ (RMi) closing bell: the sector stumbled
August 15, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
August 15, 2018
RegMed Investors’ (RMi) pre-open: are we just buying into volatility?
August 14, 2018
RegMed Investors’ (RMi) closing bell: back-in the saddle again
August 14, 2018
RegMed Investors’ (RMi) pre-open: it’s a bouncer after yesterday’s trounce
August 13, 2018
RegMed Investors’ (RMi) closing bell: the sector got squeezed
August 13, 2018
RegMed Investors’ (RMi) pre-open: what will the day bring?
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
